Biotech · Private company
Ascentage Pharma Group Inc.
Track this companyFree. Adds Ascentage Pharma Group Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2513 recruiting or active
Pipeline programs33From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline33
- Azacitidine InjectionPhase 3 · Higher-risk Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- BosutinibPhase 3 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BTK inhibitorPhase 3 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's choice of TKIPhase 3 · Ph+ ALLClinicalTrials.gov · fetched Nov 12, 2026
- Lisaftoclax (APG-2575)Phase 3 · Higher-risk Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- lisaftoclax +BTK inhibitorPhase 3 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- olverembatinibPhase 3 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- OlverembatinibPhase 3 · Ph+ ALLClinicalTrials.gov · fetched Nov 12, 2026
- 5-azacitidinePhase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- APG 2575 ramp up armPhase 2 · AML, AdultClinicalTrials.gov · fetched Nov 12, 2026
- APG-115Phase 2 · T-Prolymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- APG-115Phase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- APG-1252Phase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- APG-1252Phase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- APG-2575Phase 2 · T-Prolymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- APG-2575Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- APG-2575 + DRdPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- APG-2575+ PdPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Phase 1b: APG-115+pembrolizumabPhase 2 · Unresectable or Metastatic Melanoma or Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- APG-115Phase 1 · Patients With Advanced Solid Tumor or LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- APG-1387 for InjectionPhase 1 · Advanced Solid Tumors or Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- APG-2575Phase 1 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- APG-3288Phase 1 · Relapsed/Refractory Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- APG-5918Phase 1 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- APG2575 400 mgPhase 1 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- APG2575 600 mgPhase 1 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- APG2575 800 mgPhase 1 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- Ascentage Pharma HQP1351 bioavailable inhibitorPhase 1 · Leukemia, Myeloid, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- BlinatumomabPhase 1 · Leukemia, Myeloid, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- LisaftoclaxPhase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)PHASE2 · NOT_YET_RECRUITING · started Jan 27, 2027ClinicalTrials.gov NCT07178912 · fetched Nov 12, 2026
- A Study of APG-3288 in Relapsed/Refractory Blood CancersPHASE1 · RECRUITING · started Mar 10, 2026ClinicalTrials.gov NCT07424833 · fetched Nov 12, 2026
- Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibPHASE2 · RECRUITING · started Oct 13, 2025ClinicalTrials.gov NCT06817720 · fetched Nov 12, 2026
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).PHASE3 · RECRUITING · started Jan 22, 2025ClinicalTrials.gov NCT06641414 · fetched Nov 12, 2026
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Aug 6, 2024ClinicalTrials.gov NCT06401603 · fetched Nov 12, 2026
- Study of Olverembatinib (HQP1351) in Patients With CML-CPPHASE3 · RECRUITING · started Feb 5, 2024ClinicalTrials.gov NCT06423911 · fetched Nov 12, 2026
- Global Trial in APG2575 for Patients With CLL/SLLPHASE3 · RECRUITING · started Dec 20, 2023ClinicalTrials.gov NCT06104566 · fetched Nov 12, 2026
- A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)PHASE3 · RECRUITING · started Aug 31, 2023ClinicalTrials.gov NCT06051409 · fetched Nov 12, 2026
- Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasPHASE1 · UNKNOWN · started Sep 30, 2022ClinicalTrials.gov NCT05415098 · fetched Nov 12, 2026
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaPHASE1_PHASE2 · UNKNOWN · started Dec 23, 2021ClinicalTrials.gov NCT04942067 · fetched Nov 12, 2026
- A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerPHASE1_PHASE2 · SUSPENDED · started Aug 13, 2021ClinicalTrials.gov NCT04946864 · fetched Nov 12, 2026
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · UNKNOWN · started Jul 30, 2021ClinicalTrials.gov NCT04964518 · fetched Nov 12, 2026
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLPHASE2 · RECRUITING · started Jul 12, 2021ClinicalTrials.gov NCT04496349 · fetched Nov 12, 2026
- APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaPHASE1 · COMPLETED · started May 30, 2021ClinicalTrials.gov NCT04260217 · fetched Nov 12, 2026
- A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyPHASE1_PHASE2 · WITHDRAWN · started Dec 15, 2020ClinicalTrials.gov NCT04354727 · fetched Nov 12, 2026
- A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSPHASE1_PHASE2 · UNKNOWN · started Dec 4, 2020ClinicalTrials.gov NCT04358393 · fetched Nov 12, 2026
- Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerPHASE1_PHASE2 · TERMINATED · started Aug 20, 2020ClinicalTrials.gov NCT04210037 · fetched Nov 12, 2026
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLPHASE1 · RECRUITING · started Mar 2, 2020ClinicalTrials.gov NCT04215809 · fetched Nov 12, 2026
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLPHASE1 · RECRUITING · started Jan 9, 2020ClinicalTrials.gov NCT04260022 · fetched Nov 12, 2026
- APG-115 in Salivary Gland Cancer TrialPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 28, 2019ClinicalTrials.gov NCT03781986 · fetched Nov 12, 2026
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 29, 2018ClinicalTrials.gov NCT03611868 · fetched Nov 12, 2026
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesEARLY_PHASE1 · UNKNOWN · started Aug 7, 2018ClinicalTrials.gov NCT03537482 · fetched Nov 12, 2026
- APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesPHASE1 · COMPLETED · started Nov 21, 2017ClinicalTrials.gov NCT03386526 · fetched Nov 12, 2026
- A Study of APG-1252 in Patients With SCLC or Other Solid TumorsPHASE1 · COMPLETED · started Feb 12, 2017ClinicalTrials.gov NCT03080311 · fetched Nov 12, 2026
- APG-115 in Patients With Advanced Solid Tumors or LymphomasPHASE1 · COMPLETED · started Oct 1, 2016ClinicalTrials.gov NCT02935907 · fetched Nov 12, 2026